Sorrento Therapeutics Inc (SRNE.OQ)
7.55USD
23 May 2018
$0.30 (+4.14%)
$7.25
$7.25
$7.62
$7.25
229,141
731,562
$10.65
$1.50
About
Overall
| Beta: | 1.68 |
| Market Cap(Mil.): | $137.77 |
| Shares Outstanding(Mil.): | 76.54 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| SRNE.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.06 | 32.75 |
| EPS (TTM): | -0.64 | -- | -- |
| ROI: | -12.13 | 1.57 | 14.38 |
| ROE: | -29.69 | 2.43 | 16.07 |
BRIEF-Sorrento Therapeutics Files For Resale Of Up To 1.38 Mln Shares Of Common Stock By The Selling Stockholders
* SORRENTO THERAPEUTICS INC FILES FOR RESALE OF UP TO 1.38 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2IdNCY0) Further company coverage:
BRIEF-Sorrento Therapeutics Files For Resale Of Up To 34.16 Mln Shares Of Common Stock By Selling Stockholders
* SORRENTO THERAPEUTICS INC FILES FOR RESALE OF UP TO 34.16 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [https://bit.ly/2rzywFX] Further company coverage:
BRIEF-Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing
* SORRENTO THERAPEUTICS ANNOUNCES UNSECURED $120.5M CONVERTIBLE NOTE FINANCING
BRIEF-Sorrento Therapeutics Files Prospectus Related To Offering
* SORRENTO THERAPEUTICS INC FILES PROSPECTUS RELATED TO OFFERING OF UP TO 1.4 MILLION SHARES CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2IFWs1n) Further company coverage:
BRIEF-Sorrento Therapeutics Files Prospectus Related To Offering
* SORRENTO THERAPEUTICS INC FILES PROSPECTUS RELATED TO OFFERING OF UP TO 34.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2pwUPvb) Further company coverage:
BRIEF-Sorrento Therapeutics Welcomes Jiong Shao As Chief Financial Officer
* SORRENTO THERAPEUTICS WELCOMES JIONG SHAO AS CHIEF FINANCIAL OFFICER AND REAFFIRMS INTENT TO SEEK NASDAQ/HKSE DUAL LISTING IN 2018
BRIEF-Sorrento Says Its CAR-T Cell Therapy Showed Therapeutic Activity In Stage IV Pancreas Cancer In Early Stage Trial
* SORRENTO THERAPEUTICS AUTOLOGOUS ANTI-CEA CAR-T CELL THERAPY FOR LIVER METASTASES DEMONSTRATES THERAPEUTIC ACTIVITY IN STAGE IV PANCREAS CANCER IN A PHASE 1B HITM-SURE TRIAL (NCT02850536) Source text for Eikon: Further company coverage:
FDA approves Sorrento's non-opioid painkiller patch, shares jump
Sorrento Therapeutics Inc said on Wednesday the U.S. Food and Drug Administration has approved ZTlido, its non-opioid painkiller patch for nerve pain related to shingles, which it plans to launch later this year.
UPDATE 2-FDA approves Sorrento's non-opioid painkiller patch, shares jump
* To compete with Endo's Lidoderm, generics (Adds background, company and analyst comments)
BRIEF-Sorrento Therapeutics' Unit Receives FDA Approval For Non-Opioid Ztlido
* SORRENTO THERAPEUTICS SUBSIDIARY, SCILEX, RECEIVES US FDA APPROVAL FOR NON-OPIOID ZTLIDO™ (LIDOCAINE TOPICAL SYSTEM) 1.8% FOR PHN PAIN
Competitors
| Price | Chg | |
|---|---|---|
| Genmab A/S (GEN.CO) | kr.1,227.00 | -5.50 |
| Avanir Pharmaceuticals Inc (AVNR.OQ) | -- | -- |
| Eisai Co., Ltd (4523.T) | ¥8,013 | -- |
| AnaptysBio Inc (ANAB.OQ) | $86.26 | +0.06 |
| Bristol-Myers Squibb Co (BMY.N) | $52.50 | +0.16 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $882.65 | -- |
Estimates